FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

FEINBERG LARRY N 		2. Issuer Name and Ticker or Trading Symbol

SOLENO THERAPEUTICS INC [ SLNO ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      __ X __ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

262 HARBOR DRIVE, 3RD FL 		3. Date of Earliest Transaction (MM/DD/YYYY)

3/14/2019
(Street)

STAMFORD, CT 06902
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, par value $0.001 per share ("Common Stock")   3/14/2019     P    900   A $1.1995   2520246   I   See footnote   (1) (4) (5)
Common Stock   3/14/2019     P    95235   A $1.2229   2615481   I   See footnote   (1) (4) (5)
Common Stock   3/14/2019     P    192   A $1.1995   834883   I   See footnote   (2) (4) (5)
Common Stock   3/14/2019     P    20360   A $1.2229   855243   I   See footnote   (2) (4) (5)
Common Stock   3/14/2019     P    128   A $1.1995   329286   I   See footnote   (3) (4) (5)
Common Stock   3/14/2019     P    13548   A $1.2229   342834   I   See footnote   (3) (4) (5)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
(1)  These securities are owned by Oracle Partners, LP. ("Partners").
(2)  These securities are owned by Oracle Ten Fund, L.P. ("Ten Fund").
(3)  These securities are owned by Oracle Institutional Partners, L.P. ("Institutional Partners")
(4)  Larry N. Feinberg serves as the managing member of Oracle Associates, LLC, the general partner of Partners, Institutional Partners and Ten Fund, and accordingly, may be deemed to be the indirect beneficial owner of the shares beneficially owned by Partners, Institutional Partners and Ten Fund. Mr. Feinberg is the sole shareholder, director and president of Oracle Investment Management, Inc., which serves as investment manager to Partners, Institutional Partners and Ten Fund, and accordingly, may be deemed to be the beneficial owner of the shares beneficially owned by Partners, Institutional Partners and Ten Fund.
(5)  Each of the Reporting Persons identified in this statement disclaims beneficial ownership of the securities described in this statement, except to the extent of their individual respective pecuniary interest in such securities. The filing of this statement shall not be deemed an admission that any of the Reporting Persons identified in this statement are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owner of any securities specified in this statement other than those directly beneficially owned by them.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
FEINBERG LARRY N
262 HARBOR DRIVE, 3RD FL
STAMFORD, CT 06902
X

ORACLE PARTNERS LP
262 HARBOR DRIVE, 3RD FL
STAMFORD, CT 06902
X


Signatures
/s/ Larry N. Feinberg 3/18/2019
** Signature of Reporting Person Date

ORACLE PARTNERS, L.P., By: Oracle Associates, LLC, its General Partner, By: /s/ Larry N. Feinberg, Managing Member 3/18/2019
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Soleno Therapeutics (NASDAQ:SLNO)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Soleno Therapeutics Charts.
Soleno Therapeutics (NASDAQ:SLNO)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Soleno Therapeutics Charts.